Guidance Issued for Safe Use of GLP-1 RAs in the Perioperative Period
By Elana Gotkine HealthDay Reporter
TUESDAY, Nov. 5, 2024 -- In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, recommendations are presented for the safe use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the perioperative period.
Noting that GLP-1 RAs have revolutionized the care of patients with metabolic disease, Tammy L. Kindel, M.D., Ph.D., from the Medical College of Wisconsin in Milwaukee, and colleagues developed recommendations for the safe use of GLP-1 RAs in the perioperative period.
The authors recommend that GLP-1 RA use in the perioperative period should be based on shared decision-making of the patient with procedural, anesthesia, and prescribing care teams, focusing on balancing the metabolic need for GLP-1 RAs with patient risk. Variables that elevate the risk for delayed gastric emptying and aspiration should be considered, with their assessment occurring with enough time before surgery to allow for adjustments in perioperative care, if needed. Safe GLP-1 RA use should include efforts to minimize the aspiration risk of delayed gastric emptying, which can be achieved by preoperative diet modification and/or altering anesthesia. In cases with concern for delayed gastric emptying, preoperative diet modification (a preoperative liquid diet for at least 24 hours) can be utilized.
"This multisociety clinical practice document should be considered guidance and not an evidence-based guideline, focusing on shared decision-making and balancing safety processes with therapeutic metabolic need for the safe continuation of surgical and procedural care in patients taking GLP-1 RAs," the authors write.
Several authors disclosed ties to the pharmaceutical and medical device industries.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
ASCO: Durvalumab Plus FLOT Beneficial for Resectable Gastric, GE Junction Cancer
THURSDAY, June 5, 2025 -- For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel...
Endolymphatic Sac Decompression Effective for Vertigo, Migraine
WEDNESDAY, May 28, 2025 -- For Meniere disease (MD) patients with migraine, endolymphatic sac decompression (ELSD) is effective, providing postoperative relief of vertigo and...
One-Week Radiotherapy for Breast Cancer Safe, Effective Up to 10 Years
TUESDAY, May 27, 2025 -- A five-fraction, one-week schedule of adjuvant breast radiotherapy is as safe and effective as a standard three-week schedule for patients with invasive...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.